Komipharm International Co. Ltd Total Liabilities
Komipharm International Co. Ltd total liabilities. Based on the latest financial reports, Komipharm International Co. Ltd (041960) has total liabilities worth ₩61.86 Billion KRW (≈ $41.92 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Komipharm International Co. Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Komipharm International Co. Ltd (2011–2025)
Total liabilities of Komipharm International Co. Ltd from 2011 to 2025. This chart illustrates how Komipharm International Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Komipharm International Co. Ltd (041960) investment intensity to see how much of total assets are deployed in long-term investments.
Komipharm International Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Komipharm International Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiayuan Science and Technology Co.Ltd.
SHE:301117
|
China | CN¥252.70 Million |
|
Zhenhai PetroChem Engineering
SHG:603637
|
China | CN¥265.87 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩239.83 Billion |
|
Tidewater Midstream and Infrastructure Ltd
TO:TWM
|
Canada | CA$969.10 Million |
|
Roma Green Finance Limited Ordinary Shares
NASDAQ:ROMA
|
USA | $2.84 Million |
|
Wuhan Ligong Guangke Co Ltd
SHE:300557
|
China | CN¥754.18 Million |
|
Atria Oyj A
HE:ATRAV
|
Finland | €562.70 Million |
|
Glarner Kantonalbank
SW:GLKBN
|
Switzerland | CHF8.79 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Komipharm International Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Komipharm International Co. Ltd total assets.
Liquidity & Leverage Metrics
Komipharm International Co. Ltd Total Liabilities Ratios Explained
Komipharm International Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Komipharm International Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Komipharm International Co. Ltd (2011–2025)
The table below shows the annual total liabilities of Komipharm International Co. Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩61.86 Billion ≈ $41.92 Million |
+8.09% |
| 2024-12-31 | ₩57.23 Billion ≈ $38.78 Million |
-2.31% |
| 2023-12-31 | ₩58.58 Billion ≈ $39.70 Million |
+14.60% |
| 2022-12-31 | ₩51.12 Billion ≈ $34.64 Million |
+4.75% |
| 2021-12-31 | ₩48.80 Billion ≈ $33.07 Million |
+6.93% |
| 2020-12-31 | ₩45.64 Billion ≈ $30.93 Million |
-12.85% |
| 2019-12-31 | ₩52.37 Billion ≈ $35.49 Million |
+12.58% |
| 2018-12-31 | ₩46.52 Billion ≈ $31.52 Million |
-3.09% |
| 2017-12-31 | ₩48.00 Billion ≈ $32.53 Million |
-15.26% |
| 2016-12-31 | ₩56.64 Billion ≈ $38.38 Million |
-1.08% |
| 2015-12-31 | ₩57.26 Billion ≈ $38.80 Million |
-19.62% |
| 2014-12-31 | ₩71.24 Billion ≈ $48.28 Million |
+11.18% |
| 2013-12-31 | ₩64.08 Billion ≈ $43.42 Million |
+75.98% |
| 2012-12-31 | ₩36.41 Billion ≈ $24.68 Million |
+46.34% |
| 2011-12-31 | ₩24.88 Billion ≈ $16.86 Million |
-- |
About Komipharm International Co. Ltd
Komipharm International Co., Ltd. manufactures and sells veterinary vaccines, veterinary pharmaceuticals and disinfectants, and bio-fertilizers internationally. It also develops anticancer drugs and pain-relieving agents, which include Kominox, an arsenic-based oral drug; and Panaphix, a non-narcotic cancer pain reliever, as well as provides clinical pathological experiment, test, and analysis se… Read more